Skip to main content
Contact Us
Subscribe
E-Edition
74°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunome Inc
(NQ:
IMNM
)
10.81
+0.99 (+10.08%)
Streaming Delayed Price
Updated: 12:50 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunome Inc
< Previous
1
2
3
4
5
6
Next >
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
From
Immunome, Inc.
Via
Business Wire
Analyst Expectations For Immunome's Future
November 08, 2024
Via
Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
November 08, 2024
Via
Benzinga
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
November 05, 2024
From
Immunome, Inc.
Via
Business Wire
Evaluating Immunome: Insights From 4 Financial Analysts
May 31, 2024
Via
Benzinga
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
October 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
October 18, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
October 11, 2024
Via
Benzinga
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 08, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
October 01, 2024
Via
Benzinga
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
September 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Stock Sees RS Rating Jump To 91
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
August 12, 2024
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
July 25, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Phil Tsai as Chief Technical Officer
June 27, 2024
From
Immunome, Inc.
Via
Business Wire
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
May 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
May 21, 2024
Via
Benzinga
Immunome Announces Completion of Purchase of Assets from Atreca
May 20, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
May 17, 2024
From
Immunome, Inc.
Via
Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024
May 14, 2024
IMNM stock results show that Immunome beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 2024 Bank of America Healthcare Conference
May 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Kinney Horn as Chief Business Officer
May 02, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Sandra M. Swain to Board of Directors
April 25, 2024
From
Immunome
Via
Business Wire
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
April 05, 2024
From
Immunome, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.